2019
- We closed more than 300 licensing agreements in over 55 countries till today.
2018
- Submission of our first own ANDA in the US.
2017
- The Riverside Company invests in Alter Pharma Group.
2016
- Incorporation of Milla Pharmaceuticals Inc. in the USA.
- First own submission in the USA.
2015
- First marketing authorization granted in the USA.
2014
- Extension to supply related activities by Generic Pharma International Limited, based in Ireland.
2013
- Launch of the first oral product: Paracetamol tabs.
2012
- Expansion to many different countries, first Paracetamol IV submission in the US.
- Opening of Dublin office.
2011
- Move to Anderlecht, Brussels office.
- Launch of Paracetamol IV in different countries.
2010
- Creation of Alter Pharma NV to support new ventures in developments of other forms.
- Decentralized Procedure (DCP) approval for Paracetamol IV in 20 countries.
2009
- Submission of Paracetamol IV, Zoledronic acid 4mg/5ml.
- Marketing Authorization (MA) for Pantoprazole IV.
2008
First submission of Pantoprazole IV.
2007
Neogen was founded for the developments of the following injectable products:
- Paracetamol IV,
- Pantoprazole IV,
- Zoledronic acid IV,
- Teicoplanine IV,
- Fluconazole IV.